Display Settings:

Format
Sort by

Send to:

Choose Destination

Results: 4

1.

Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.

Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M.

Diab Vasc Dis Res. 2013 May;10(3):239-45. doi: 10.1177/1479164112460253. Epub 2012 Oct 22.

PMID:
23091285
[PubMed - indexed for MEDLINE]
Free Article
2.

[Pentosidine: a new biomarker in diabetes mellitus complications].

Morales S, García-Salcedo JA, Muñoz-Torres M.

Med Clin (Barc). 2011 Mar 19;136(7):298-302. doi: 10.1016/j.medcli.2009.12.001. Epub 2010 Mar 11. Review. Spanish.

PMID:
20226481
[PubMed - indexed for MEDLINE]
3.

[Measurement of plasma pentosidine and the clinical significance in diagnosis of diabetic nephropathies].

Sanaka T, Hosokawa T.

Nihon Rinsho. 2005 Jun;63 Suppl 6:373-8. Review. Japanese. No abstract available.

PMID:
15999737
[PubMed - indexed for MEDLINE]
4.

Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.

Yamagishi S, Matsui T, Nakamura K.

Curr Drug Targets. 2007 Oct;8(10):1138-43. Review.

PMID:
17979674
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk